Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Autor: Vermunt, L., Sikkes, S. A. M., van den Hout, A., Handels, R., Bos, I., van der Flier, W. M., Kern, S., Ousset, P. -J., Maruff, P., Skoog, I., Verhey, F. R. J., Freund-Levi, Y., Tsolaki, M., Wallin, A. K., Olde Rikkert, M., Soininen, H., Spiru, L., Zetterberg, H., Blennow, K., Scheltens, P., Muniz-Terrera, G., Visser, P. J., Vellas, B., Reynish, E., Ousset, P. J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J. P., Zekry, D. S., Boada, M., Dartigues, J. F., Olde-Rikkert, M. G. M., Rigaud, A. S., Winblad, B., Malick, A., Sinclair, A., Frolich, L., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldemar, G., Bullock, R., Rodriguez, G., Jones, R. W., Stiens, G., Stoppe, G., Eriksdotter Jonhagen, M., Cherubini, A., Lage, P. M., Gomez-Isla, T., Camus, V., Aguera-Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N.

Publikováno v: Alzheimer Disease Neuroimaging Initiative, AIBL Research Group & ICTUS/DSA study groups 2019, ' Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype ', Alzheimer's and Dementia, vol. 15, no. 7, pp. 888-898 . https://doi.org/10.1016/j.jalz.2019.04.001
Alzheimer's & Dementia, 15(7), 888-898. Elsevier Science
Alzheimer's & Dementia, 15, 7, pp. 888-898
Alzheimer's & Dementia, 15, 888-898
Alzheimer's and Dementia, 15(7), 888-898. Elsevier
Alzheimer's and Dementia, 15(7), 888-898. Elsevier Inc.
Vermunt, L, Sikkes, S A M, van den Hout, A, Handels, R, Bos, I, van der Flier, W M, Kern, S, Ousset, P-J, Maruff, P, Skoog, I, Verhey, F R J, Freund-Levi, Y, Tsolaki, M, Wallin, Å K, Olde Rikkert, M, Soininen, H, Spiru, L, Zetterberg, H, Blennow, K, Scheltens, P, Muniz-Terrera, G, Visser, P J, AIBL Research Group & Alzheimer Disease Neuroimaging Initiative 2019, ' Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype ', Alzheimer's and Dementia, vol. 15, no. 7, pp. 888-898 . https://doi.org/10.1016/j.jalz.2019.04.001
Alzheimer's & Dementia, Vol. 15, No 7 (2019) pp. 888-898

Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration.M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c03928efd25674f60e863f36648f9fe0
https://doi.org/10.1016/j.jalz.2019.04.001

Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study

Autor: Rombach, I., Iftikhar, M., Jhuti, G.S., Gustavsson, A., Lecomte, P., Belger, M., Handels, R., Castro Sanchez, A.Y., Kors, J., Hopper, L., Olde Rikkert, M., Selbæk, G., Stephan, A., Sikkes, S.A.M., Woods, B., Gonçalves-Pereira, M., Zanetti, O., Ramakers, I.H.G.B., Verhey, F.R.J., Gallacher, J., Actifcare Consortium, LeARN Consortium, Landeiro, F., Gray, A.M., ROADMAP Consortium

Purpose\ud \ud The Quality of Life Alzheimer’s Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness analyses, utilities based on the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::8f83e847d83531b22f2d86879c056584
https://eprints.whiterose.ac.uk/186514/1/Obtaining.pdf

Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

Autor: Frederiksen, K.S. Nielsen, T.R. Appollonio, I. Andersen, B.B. Riverol, M. Boada, M. Ceccaldi, M. Dubois, B. Engelborghs, S. Frölich, L. Hausner, L. Gabelle, A. Gabryelewicz, T. Grimmer, T. Hanseeuw, B. Hort, J. Hugon, J. Jelic, V. Koivisto, A. Kramberger, M.G. Lebouvier, T. Lleó, A. de Mendonça, A. Nobili, F. Ousset, P.-J. Perneczky, R. Olde Rikkert, M. Robinson, D. Rouaud, O. Sánchez, E. Santana, I. Scarmeas, N. Sheardova, K. Sloan, S. Spiru, L. Stefanova, E. Traykov, L. Yener, G. Waldemar, G.

Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::c27c704cec71f106fa14a97b6f0ea6c4
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102879

Gait speed, cognition and falls in people living with mild-to-moderate Alzheimer disease: data from NILVAD

Autor: Dyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Segurado, R., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. William, Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., Breuilh, L., Daly, L., Hendrix, S., Aisen, P., Gaynor, S., Sheikhi, A., Taekema, D. G., Verhey, F. R., Nemni, R., Nobili, F., Franceschi, M., Frisoni, G., Zanetti, O., Konsta, A., Anastasios, O., Nenopoulou, S., Tsolaki-Tagaraki, F., Pakaski, M., Dereeper, O., Sayette, V. D. L., Sénéchal, O., Lavenu, I., Devendeville, A., Calais, G., Crawford, F., Mullan, M., Aalten, P., Berglund, M. A., Claassen, J. A., De Heus, R. A., De Jong, D. L. K., Godefroy, O., Hutchinson, S., Ioannou, A., Jonsson, M., Kent, A., Kern, J., Nemtsas, P., Panidou, M.-K., Abdullah, L., Paris, D., Santoso, A. M., van Spijker, G. J., Spiliotou, M., Thomoglou, G., Wallin, A., NILVAD Study Group

Publikováno v: BMC Geriatrics, 20, 1
BMC Geriatrics
BMC Geriatrics, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Geriatrics, 20

Background Previous evidence suggests that slower gait speed is longitudinally associated with cognitive impairment, dementia and falls in older adults. Despite this, the longitudinal relationship between gait speed, cognition and falls in those with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2988a390ee27e1720e8bb728e8738c
https://hdl.handle.net/2066/220655

Predicting the Rate of Cognitive Decline in Alzheimer Disease

Autor: Canevelli, Marco, Kelaiditi, Eirini, Del Campo, Natalia, Bruno, Giuseppe, Vellas, Bruno, Cesari, Matteo, Vellas, B., Reynish, E., Ousset, P. J., Andrieu, S., Burns, A., Pasquier, F., Frisoni, G., Salmon, E., Michel, J. P., Zekry, D. S., Boada, M., Dartigues, J. F., Olde Rikkert, M. G. M., Rigaud, A. S., Winblad, B., Malick, A., Sinclair, A., Frölich, L., Scheltens, P., Ribera, C., Touchon, J., Robert, P., Salva, A., Waldmar, G., Bullock, R., Costa Tsolaki, M., Rodriguez, G., Spiru, L., Jones, R. W., Stiens, G., Stoppe, G., Eriksdotter Jönhagen, M., Cherubini, A., Lage, P. M., Gomez Isla, T., Camus, V., Agüera Morales, E., Lopez, F., Savy, S., Cantet, C., Coley, N.

Publikováno v: Alzheimer Disease and Associated Disorders, 30(3), 237-242. Lippincott Williams and Wilkins
The DSA Group & ICTUS/DSA group 2016, ' Predicting the rate of cognitive decline in Alzheimer disease : Data from the ICTUS study ', Alzheimer Disease and Associated Disorders, vol. 30, no. 3, pp. 237-242 . https://doi.org/10.1097/WAD.0000000000000124

Background: Different rates of cognitive progression have been observed among Alzheimer disease (AD) patients. The present study aimed at evaluating whether the rate of cognitive worsening in AD may be predicted by widely available and easy-to-assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd07c8270c0d4b4f8aa00b8f24f0663
https://doi.org/10.1097/wad.0000000000000124